RC48-ADC in Breast Cancer
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Breast Cancer
DRUG: Disitamab vedotin
Progression-Free Survival, The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first., From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
Adverse events, Adverse events during Disitamab Vedotin regimen will be assessed according to the NCI CTCAE v5.0., From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.